Reviva Pharmaceuticals Announces First Patients Dosed in Pivotal Phase 3 Study and Long-Term Safety Trial Evaluating Brilaroxazine for the Treatment of Schizophrenia

Feb 1, 2022 | Press Releases

– RECOVER is a Phase 3, randomized, double-blind study with registrational intent – – Reviva anticipates expanding the clinical development of brilaroxazine into other neuropsychiatric indications – CUPERTINO, Calif., Feb. 01, 2022 —...

Reviva Pharmaceuticals Holdings, Inc. Receives FDA May Proceed Letter for Pivotal Phase 3 Clinical Trial and Long-Term Safety Trial Evaluating Brilaroxazine For The Treatment of Schizophrenia

Jan 10, 2022 | Press Releases

– Brilaroxazine is a novel serotonin and dopamine receptor modulator currently being developed for diseases with dysfunctional serotonin signaling including neuropsychiatric and pulmonary indications – – Initiation of both Phase 3 trials is expected...

Reviva Pharmaceuticals to Participate in the Upcoming January Virtual Investor Conferences

Dec 20, 2021 | Press Releases

CUPERTINO, Calif., Dec. 20, 2021 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva Pharmaceuticals Holdings, Inc. Reports Third Quarter 2021 Financial Results and Recent Business Highlights

Nov 15, 2021 | Press Releases

– Initiation of a pivotal Phase 3 trial evaluating the efficacy and safety of brilaroxazine for the treatment of schizophrenia expected by year-end – – Additional Phase 3 trial evaluating the long-term safety of brilaroxazine in adult patients with...

Reviva Pharmaceuticals to Present at the Upcoming Benzinga Healthcare Small Cap Conference

Sep 15, 2021 | Press Releases

CUPERTINO, Calif., Sept. 15, 2021 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Sep 2, 2021 | Press Releases

CUPERTINO, Calif., Sept. 02, 2021 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...